🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. PRAVASTATIN

    The George Institute

    Patients with severe and radio-induced breast fibrosis after breast cancer

    phase 2 small molecule active

    1 trial

  2. Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

    CASI Pharmaceuticals

    Carcinoid Tumor

    phase 2 small molecule completed

    1 trial

  3. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Pitolisant oral tablets

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  5. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial

  6. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

  7. Placebo to AVTX-009, AVTX-009

    Avalo Therapeutics

    Hidradenitis suppurativa (HS)

    phase 2 small molecule active

    1 trial

  8. Placebo, BFB759

    Blue Earth Diagnostics Ireland Ltd

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  9. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  10. Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Oral Mucositis

    phase 2 small molecule active

    1 trial

  11. RAD001

    Ultragenyx UK Limited

    PTEN Gene Mutation

    phase 2 small molecule completed

    1 trial

  12. RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB

    Takeda

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    phase 2 small molecule active

    1 trial

  13. REGN2477+REGN1033

    Regeneron UK Limited

    Sporadic Inclusion Body Myositis

    phase 2 small molecule terminated

    1 trial

  14. RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR GETUG P16)

    CERO THERAPEUTICS HOLDINGS, INC.

    RElapse in previously irradiated Prostate bed

    phase 2 other active

    1 trial

  15. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  16. Rademikibart in prefilled syringe

    S.L

    COPD Acute Exacerbation

    phase 2 other active

    1 trial

  17. Rademikibart in prefilled syringe

    S.L

    Asthma Acute

    phase 2 other active

    1 trial

  18. Radiation+PD-1 Ab

    The First People's Hospital of Lianyungang

    Proton Therapy

    phase 2 other active

    1 trial

  19. Radiation: 131I-MIBG

    United Therapeutics Europe Ltd

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  20. Radiation: Proton Therapy+PD-1 Ab

    The First People's Hospital of Lianyungang

    Proton Therapy

    phase 2 other active

    1 trial

  21. Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

  22. Radio-guided sentinel node biopsy

    Hospital Authority, Hong Kong

    Cancer of the Breast

    phase 2 other terminated

    1 trial

  23. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  24. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources